Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.
UNAIDS, Uganda.
Biomed Res Int. 2020 May 18;2020:2875864. doi: 10.1155/2020/2875864. eCollection 2020.
In 2013, the World Health Organization (WHO) revised the 2012 guidelines on use of antiretroviral drugs (ARVs) for the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV). The new guidelines recommended lifelong antiretroviral therapy (ART) for all HIV-positive pregnant and breastfeeding women irrespective of CD4 count or clinical stage (also referred to as Option B+). Uganda started implementing Option B+ in 2012 basing on the 2012 WHO guidelines. Despite the impressive benefits of the Option B+ strategy, implementation challenges, including cost burden and mother-baby pairs lost to follow-up, threatened its overall effectiveness. The researchers were unable to identify any studies conducted to assess costs and cost drivers associated with provision of Option B+ services to mother-baby pairs in HIV care in Uganda. Therefore, this study determined costs and cost drivers of providing Option B+ services to mother-baby pairs over a two-year period (2014-2015) in selected health facilities in Jinja district, Uganda.
The estimated costs of providing Option B+ to mother-baby pairs derived from the provider perspective were evaluated at four health centres (HC) in Jinja district. A retrospective, ingredient-based costing approach was used to collect data for 2014 as base year using a standardized cost data capture tool. All costs were valued in United States dollars (USD) using the 2014 midyear exchange rate. Costs incurred in the second year (2015) were obtained by inflating the 2014 costs by the ratio of 2015 and 2014 USA Gross Domestic Product (GDP) implicit price deflator.
The average total cost of Option B+ services per HC was 66,512.7 (range: 32,168.2-102,831.1) USD over the 2-year period. The average unit cost of Option B+ services per mother-baby pair was USD 441.9 (range: 422.5-502.6). ART for mothers was the biggest driver of total mean costs (percent contribution: 62.6%; range: 56.0%-65.5%) followed by facility personnel (percent contribution: 8.2%; range: 7.7%-11.6%), and facility-level monitoring and quality improvement (percent contribution: 6.0%; range: 3.2%-12.3%). . ART for mothers was the major cost driver. Efforts to lower the cost of ART for PMTCT would make delivery of Option B+ affordable and sustainable.
2013 年,世界卫生组织(WHO)修订了 2012 年关于使用抗逆转录病毒药物(ARV)预防母婴传播(PMTCT)艾滋病毒(HIV)的指南。新指南建议所有 HIV 阳性的孕妇和哺乳期妇女终身接受抗逆转录病毒治疗(ART),无论 CD4 计数或临床阶段如何(也称为 B+选项)。乌干达于 2012 年根据 2012 年世卫组织指南开始实施 B+选项。尽管 B+选项策略带来了令人印象深刻的好处,但包括成本负担和母婴对失去随访在内的实施挑战,威胁到其整体效果。研究人员无法确定任何评估在乌干达 HIV 护理中向母婴对提供 B+服务的成本和成本驱动因素的研究。因此,本研究旨在确定在乌干达 Jinja 区选定的四个卫生中心(HC)为母婴对提供 B+服务两年期间(2014-2015 年)的成本和成本驱动因素。
从提供者的角度评估了在 Jinja 区四个卫生中心(HC)提供 B+选项给母婴对的估计成本。使用回溯性、基于成分的成本核算方法,使用标准化成本数据捕获工具收集了 2014 年作为基础年的数据。所有成本均使用 2014 年年中汇率换算成美元(USD)。第二年(2015 年)发生的成本是通过将 2014 年的成本乘以 2015 年和 2014 年美国国内生产总值(GDP)隐含物价平减指数的比值来获得的。
在 2 年期间,每个 HC 的 B+服务平均总成本为 66512.7 美元(范围:32168.2-102831.1)。每个母婴对的 B+服务平均单位成本为 441.9 美元(范围:422.5-502.6)。母亲的 ART 是总平均成本的最大驱动因素(贡献百分比:62.6%;范围:56.0%-65.5%),其次是设施人员(贡献百分比:8.2%;范围:7.7%-11.6%)和设施级监测和质量改进(贡献百分比:6.0%;范围:3.2%-12.3%)。母亲的 ART 是主要的成本驱动因素。降低 PMTCT 的 ART 成本的努力将使提供 B+选项具有成本效益和可持续性。